Vertex Pharmaceuticals Inc (VRTX) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.

Total Cash From Operating Activities Chart for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc (VRTX) operating cash flow for FY2025 was USD 3.6B. Vertex Pharmaceuticals Inc's operating cash flow moved from USD -2.5M in 1991 to USD 3.6B in 2025 over 34 years. Operating cash flow compound annual growth rate: 5-year CAGR of 2.2%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$122.68B
Implied Share Price
$484.03
Enterprise Value
$117.01B
Revenue (TTM)
$12.59B
EBITDA
$5.10B
Profit Margin
35.00%
Trailing P/E
28.26
Forward P/E
24.88
Price/Book (MRQ)
5.99
Price/Sales (TTM)
9.75
EV/EBITDA
22.88
EV/Revenue
9.17
Dividend Yield
—
Book Value
$79.92
Free Cash Flow (FY2025)
$3.19B
Free Cash Flow Yield
2.60%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.